Clinical trials: Epidermis
EGFR Mutation-Related Tumors
A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.
- Trial name
- NCT05514496
- Testing
- NX-019
- Where
- 12 sites in United States, South Korea and 1 more
- Volunteers
- 258 people
- Sponsor
- Nalo Therapeutics Inc.
Vitiligo, Generalized
Autologous Cellular Graft in Surgical Treatment of Vitiligo
This is a double blinded self controlled randomized trial to assess Autologous Micro Cellular Grafts in surgical treatment of stable resistant vitiligo.
- Trial name
- NCT05503368
- Testing
- surgical treatment of vitiligo using NCES
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Cairo University
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Icotinib is a first-generation inhibitor of EGFR-tyrosine kinase inhibitor in patients with non-small-cell lung cancer (NSCLC). Here we will evaluate neoadjuvant Icotinib with chemotherapy prior to surgery, in patients with…
- Trial name
- NCT05132985
- Testing
- Icotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Solid Tumor
Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients
RATIONALE: Studying samples of tissue and blood in the laboratory from patients with cancer receiving epidermal growth factor receptor (EGFR) inhibitors may help doctors understand the effects of EGFR inhibitor therapy in the…
- Trial name
- NCT00483457
- Testing
- enzyme inhibitor therapy, protein expression analysis, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Neoplasm Metastasis, Colorectal Cancer
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor…
- Trial name
- OPUS (NCT00125034)
- Testing
- Cetuximab, Oxaliplatin
- Where
- 78 sites in Austria, Belgium and 11 more
- Volunteers
- 344 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Vitiligo
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
Medical approaches remain the gold standard treatment for non-segmental forms of vitiligo. Topical ruxolitinib cream has demonstrated its efficacy and good tolerance for treating vitiligo.
- Trial name
- PREVENT (NCT05872477)
- Testing
- Ruxolitinib Topical
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Vitiligo
Comparing Recipient Site Preparation Using Dermabrasion, Dermaroller and Liquid Nitrogen Induced Blister in Non Cultured Epidermal Cell Suspension in Stable Vitiligo
A COMPARATIVE STUDY BETWEEN RECEPIENT SITE PREPARATION USING DERMABRASION, LIQUID NITROGEN INDUCED BLISTER AND DERMAROLLING SYSTEM IN AUTOLOGOUS NON CULTURED EPIDERMAL CELL SUSPENSION PROCEDURE IN STABLE VITILIGO PATIENTS
- Trial name
- NCT03668834
- Testing
- Dermabrasion with NCES, Dermaroller with NCES, Liquid nitrogen induced blister with NCES
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Metastatic Breast Cancer
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer
This study of hormone positive (estrogen receptor [ER]), metastatic invasive ductal breast cancer looks at functional scanning using positron emission tomography (PET) and patient response to hormone therapy.
- Trial name
- NCT00358098
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer, Solid Tumors
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2).
- Trial name
- NCT05262400
- Testing
- PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 235 people
- Sponsor
- Pfizer
Recurrent Breast Cancer
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
The purpose of this study is to find out what effects this new drug foretinib has on this type of breast cancer, called "triple negative" breast cancer because the cancer tissue is estrogen, progesterone and HER2 receptor…
- Trial name
- IND197 (NCT01147484)
- Testing
- Foretinib
- Where
- 9 sites in Canada
- Volunteers
- 47 people
- Sponsor
- NCIC Clinical Trials Group
Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well…
- Trial name
- NCT07111520
- Testing
- BNT326, Pumitamig
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 880 people
- Sponsor
- BioNTech SE
Carcinoma, Non-Small-Cell Lung
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
- Trial name
- REVEAL (NCT03761901)
- Testing
- 1L treatment, 2L Treatment, 3L treatment
- Where
- 15 sites in Belgium
- Volunteers
- 141 people
- Sponsor
- AstraZeneca
Gastric Cancer, Gastroesophageal Junction Cancer
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
This study will evaluate overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.
- Trial name
- NCT01813253
- Testing
- Irinotecan, Nimotuzumab
- Where
- 37 sites in Japan, South Korea and 1 more
- Volunteers
- 400 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Wrinkles, Acne Scars
Epidermal Delivery of Ani-Aging Ingredients
To assess the safety and efficacy of an ablative fractional, 2940-nm laser combined with the US Impact and cosmetic -formulations for improving the appearance of wrinkles, acne scars and pigmented skin.
- Conditions
- Wrinkles, Acne Scars, Pigmentation
- Trial name
- NCT01847066
- Testing
- Erbium 2940 plus cosmetics plus Impact, Erbium 2940 plus cosmetics
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
HER2-positive Breast Cancer, Male Breast Cancer
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
This phase I trial studies the side effects and best dose of ganetespib when given with paclitaxel, trastuzumab and pertuzumab in treating patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast…
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT02060253
- Testing
- ganetespib, paclitaxel, trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epidermal Growth Factor, Epidermal Growth Factor Receptor
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any…
- Conditions
- Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell
- Trial name
- NCT07462377
- Testing
- EPI-326
- Where
- 8 sites in United States, South Korea and 1 more
- Volunteers
- 110 people
- Sponsor
- EpiBiologics
Breast Cancer, Gastric Cancer
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
This multicenter study will assess the maximum tolerated dose (MTD) of capecitabine in combination with Kadcyla (trastuzumab emtansine) in participants with HER2-positive mBC or HER2-positive LA/mGC using a Phase 1 design…
- Trial name
- TRAXHER2 (NCT01702558)
- Testing
- Capecitabine, Trastuzumab emtansine (T-DM1)
- Where
- 40 sites in Argentina, Brazil and 10 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Colorectal Adenoma
Molecular Imaging of Epidermal Growth Factor Receptor in Colorectal Neoplasia Using Confocal Laser Endomicroscopy
The study aims to: 1. Achieve molecular imaging of EGFR in patients with colorectal neoplasia in vivo using confocal laser endomicroscopy. 2.
- Trial name
- NCT01372189
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong University
Non-Small Cell Lung Cancer
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
This is a Phase 1/2 study of PF-06747775 as a single agent and in combination with other cancer treatments in patients with advanced EGFRm NSCLC.
- Trial name
- NCT02349633
- Testing
- PF-06747775, Palbociclib, Avelumab
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Diabetic Neuropathies
Dose-effect of SSR180575 in Diabetic Neuropathy
The primary objective of this sudy is to assess the effect of two doses of SSR180575 on the rate of regeneration of epidermal nerve fibers following denervation of the epidermal layer with capsaicin in patients with diabetes…
- Trial name
- NCT00502515
- Testing
- SSR180575
- Where
- United States
- Volunteers
- 309 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.